On June 4, 2025, Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) announced that its innovative drug Aumolertinib Mesilate Tablets (trade name: Aumseqa in UK) has been granted marketing authorization by the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom. Aumseqa, as a monotherapy, is indicated for: the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. With this approval, Almonertinib has become the first innovative drug from Hansoh Pharma to be approved for the overseas market, and also the first China-developed EGFR-TKI to be launched overseas.
As the first third-generation EGFR-TKI self-developed by China, Aumolertinib Mesilate Tablets (trade name in China: Ameile) continues to expand its clinical application in the NSCLC therapeutic field. To date, supported by multiple pivotal registered clinical studies, four indications of Ameile has been approved by China’s NMPA, covering locally advanced or metastatic NSCLC (Stage III–IV), unresectable locally advanced NSCLC (Stage III), and early to intermediate-stage NSCLC (Stage II–III). This makes Ameile, the China-developed third-generation EGFR-TKI, with the most approved indications and the broadest therapeutic coverage to date. In addition, the marketing authorization application for Ameile in combination with chemotherapy as a first-line treatment for EGFR-sensitive, locally advanced or metastatic NSCLC was accepted by NMPA in November 2024.
Hansoh Pharma will continue to advance the regulatory submission of Ameile to the European Medicines Agency (EMA), aiming to benefit more patients globally.
About Ameile
As China's first original third-generation EGFR-TKI, Ameile (Aumolertinib Mesilate Tablets) features good liposolubility and stability, allowing it to better penetrate the blood-brain barrier with a low incidence of adverse reactions. Currently, Ameile has been approved for four indications: second-line treatment of patients with locally advanced or metastatic NSCLC with T790M mutation, who have progressed on or after EGFR-TKI therapy; first-line treatment for adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitute mutation positive; treatment of patients with locally advanced, unresectable（Stage III）non-small cell lung cancer ("NSCLC") whose disease has not progressed following definitive platinum-based chemoradiotherapy whose tumors have epidermal growth factor receptor ("EGFR") exon 19 deletions or exon 21 (L858R) substitute mutations; adjuvant treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) mutations, and who have undergone tumor resection.
About Hansoh Pharma
Hansoh Pharma is a leading pharmaceutical company in Greater China driven by innovation. It is committed to the treatment of major diseases in the areas of oncology, anti-infections, CNS diseases, metabolic diseases, as well as autoimmune diseases, and is dedicated to improving human health through continuous innovation. Hansoh Pharma has been ranked among the top 100 global pharmaceutical companies and the top 3 best industrial enterprises in China in terms of pharmaceutical R&D pipeline for several years, and is a national key high-tech enterprise and a national technology innovation demonstration enterprise. Hansoh Pharma was listed on the Stock Exchange of Hong Kong in June, 2019 (stock code: 03692.HK).
For more information, please visit https://www.hspharm.com/.
Statements
1. This announcement is intended for healthcare professionals only and not for advertising purposes.
2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.
3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.
4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional.
Forward-Looking Statements
This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.
The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.
Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.
All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK).
